PMID- 35027069
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20231105
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jan 13
TI  - The effect of Kappaphycus alvarezii active fraction on oxidative stress and 
      inflammation in streptozotocin and nicotinamide-induced diabetic rats.
PG  - 15
LID - 10.1186/s12906-021-03496-8 [doi]
LID - 15
AB  - BACKGROUND: High glucose concentration increases the glycation process which 
      leads to oxidative stress and inflammation, that can cause complications in 
      diabetes. Several medicinal plants have been used in the treatment of diabetes 
      and its complications. One of them is Kappaphycus alvarezii, an algae that has 
      known antidiabetic abilities. This study aimed to examine the effect of K. 
      alvarezii active fraction on plasma hydrogen peroxide (H(2)O(2)) and Tumor 
      Necrosis Factor alpha (TNFalpha) levels, renal NADPH oxidase 4 (NOX4) and Nuclear Factor 
      kappa B (NFkappaB) gene expressions. METHODS: Active fraction was obtained from 
      bioassay-guided fractionation with antiglycation ability. In vivo study was 
      performed on twenty Wistar male rats. The level of H(2)O(2) was measured using 
      H(2)O(2) Assay Kit, the Optical Density value measured using spectrophotometer at 
      a wavelength of 405 nm. Plasma TNFalpha level was measured using ELISA. Renal NOX4 
      and NFkappaB gene expression was analyzed using qPCR. RESULTS: Active fraction 
      significantly reduced plasma H(2)O(2) but not TNFalpha levels. Furthermore, renal 
      NOX4 gene expression was lower in the diabetic rat group treated with active 
      fraction compared to the untreated group but not NFkappaB gene expression. 
      CONCLUSIONS: K. alvarezii active fraction has an activity to reduce plasma 
      H(2)O(2) as well as renal NOX4 gene expression. Therefore, this fraction could be 
      developed as a potential candidate for diabetes treatment through oxidative 
      stress mechanisms.
CI  - (c) 2022. The Author(s).
FAU - Yulianti, Evy
AU  - Yulianti E
AD  - Department of Biology Education, Faculty of Mathematics and Science, Universitas 
      Negeri Yogyakarta, Yogyakarta, Indonesia.
FAU - Sunarti
AU  - Sunarti
AD  - Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, 
      Universitas Gadjah Mada, Yogyakarta, Indonesia.
FAU - Wahyuningsih, Mae Sri Hartati
AU  - Wahyuningsih MSH
AUID- ORCID: 0000-0002-9274-5573
AD  - Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and 
      Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. maeshw@ugm.ac.id.
AD  - Herbal Medical Center, Faculty of Medicine, Public Health, and Nursing, 
      Universitas Gadjah Mada, Yogyakarta, Indonesia. maeshw@ugm.ac.id.
LA  - eng
GR  - KET-1467/LPDP.3/2018/ministry of finance education fund management institution 
      (lpdp)/
PT  - Journal Article
DEP - 20220113
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Preparations)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.6.3.- (NADPH Oxidase 4)
RN  - EC 1.6.3.- (Nox4 protein, rat)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/*drug therapy
MH  - Gene Expression
MH  - Hydrogen Peroxide/blood
MH  - Inflammation/*drug therapy
MH  - Male
MH  - NADPH Oxidase 4/blood
MH  - NF-kappa B/genetics
MH  - Oxidative Stress
MH  - *Phytotherapy
MH  - Plant Preparations/*therapeutic use
MH  - Rats
MH  - *Rhodophyta
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC8759202
OTO - NOTNLM
OT  - Diabetes
OT  - H2O2
OT  - K. alvarezii
OT  - NFkappaB
OT  - NOX4
OT  - TNFalpha
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/15 06:00
MHDA- 2022/02/02 06:00
PMCR- 2022/01/13
CRDT- 2022/01/14 05:31
PHST- 2021/08/20 00:00 [received]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/01/14 05:31 [entrez]
PHST- 2022/01/15 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2022/01/13 00:00 [pmc-release]
AID - 10.1186/s12906-021-03496-8 [pii]
AID - 3496 [pii]
AID - 10.1186/s12906-021-03496-8 [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2022 Jan 13;22(1):15. doi: 10.1186/s12906-021-03496-8.